See more : Kalyani Forge Limited (KALYANIFRG.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Supriya Lifescience Limited (SUPRIYA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Supriya Lifescience Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- AMTE Power plc (AMTE.L) Income Statement Analysis – Financial Results
- FrankSpeech Network, Inc. (FSBN) Income Statement Analysis – Financial Results
- Keen Vision Acquisition Corporation Ordinary Shares (KVAC) Income Statement Analysis – Financial Results
- Aftermath Silver Ltd. (AAGFF) Income Statement Analysis – Financial Results
- Lyell Immunopharma, Inc. (LYEL) Income Statement Analysis – Financial Results
Supriya Lifescience Limited (SUPRIYA.NS)
About Supriya Lifescience Limited
Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.70B | 4.61B | 5.19B | 3.85B | 3.12B | 2.78B | 2.13B |
| Cost of Revenue | 3.60B | 1.81B | 2.30B | 1.51B | 1.63B | 1.74B | 1.78B |
| Gross Profit | 2.11B | 2.80B | 2.89B | 2.34B | 1.49B | 1.04B | 350.97M |
| Gross Profit Ratio | 36.96% | 60.77% | 55.74% | 60.77% | 47.78% | 37.55% | 16.48% |
| Research & Development | 10.85M | 12.37M | 16.62M | 6.61M | 10.57M | 7.78M | 7.06M |
| General & Administrative | 231.87M | 192.26M | 137.32M | 105.17M | 104.80M | 69.50M | 162.96M |
| Selling & Marketing | 231.80M | 238.67M | 223.75M | 231.20M | 135.38M | 113.72M | 67.27M |
| SG&A | 463.67M | 430.93M | 361.07M | 336.37M | 240.18M | 183.22M | 166.47M |
| Other Expenses | 6.06M | 94.89M | 110.00K | 39.69M | 83.55M | 48.14M | -10.53M |
| Operating Expenses | 2.80B | 1.63B | 873.31M | 735.79M | 564.45M | 432.22M | 184.06M |
| Cost & Expenses | 4.04B | 3.44B | 3.17B | 2.25B | 2.19B | 2.17B | 1.96B |
| Interest Income | 83.45M | 95.59M | 74.19M | 49.91M | 21.73M | 6.24M | 103.85M |
| Interest Expense | 37.03M | 30.84M | 28.11M | 40.80M | 68.49M | 102.22M | 0.00 |
| Depreciation & Amortization | 158.11M | 118.15M | 101.18M | 67.61M | 64.05M | 54.35M | 53.32M |
| EBITDA | 1.84B | 1.38B | 2.22B | 1.78B | 1.09B | 724.67M | 266.81M |
| EBITDA Ratio | 32.19% | 30.02% | 42.46% | 46.22% | 34.95% | 25.29% | 10.34% |
| Operating Income | 1.57B | 1.17B | 2.04B | 1.66B | 1.01B | 610.98M | 166.91M |
| Operating Income Ratio | 27.55% | 25.42% | 39.34% | 43.18% | 32.35% | 21.99% | 7.84% |
| Total Other Income/Expenses | 85.25M | -629.40M | 50.88M | 28.68M | -45.80M | -39.94M | -22.27M |
| Income Before Tax | 1.66B | 1.23B | 2.07B | 1.67B | 962.27M | 571.04M | 144.64M |
| Income Before Tax Ratio | 29.05% | 26.79% | 39.90% | 43.44% | 30.88% | 20.55% | 6.79% |
| Income Tax Expense | 465.76M | 336.30M | 554.35M | 435.65M | 228.24M | 176.79M | 57.36M |
| Net Income | 1.19B | 898.57M | 1.52B | 1.24B | 734.03M | 394.24M | 87.28M |
| Net Income Ratio | 20.88% | 19.49% | 29.23% | 32.07% | 23.55% | 14.19% | 4.10% |
| EPS | 14.80 | 11.16 | 18.86 | 16.89 | 10.03 | 15.43 | 1.19 |
| EPS Diluted | 14.80 | 11.16 | 18.86 | 16.89 | 10.03 | 15.43 | 1.19 |
| Weighted Avg Shares Out | 80.48M | 80.48M | 80.48M | 73.18M | 73.18M | 25.55M | 73.18M |
| Weighted Avg Shares Out (Dil) | 80.48M | 80.48M | 80.48M | 73.18M | 73.18M | 25.55M | 73.18M |
Source: https://incomestatements.info
Category: Stock Reports